Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0114-0006 and liraglutide for preservation of beta-cell function in newly diagnosed type 1 diabetes
2014-001215-39Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2015
- Modality
- Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NNC0114-0000-0005 and liraglutide in diabetes mellitus type 1 (T1D) (4 arms), sponsored by Novo Nordisk. Primary endpoint: AUC0-4h for mixed meal tolerance test stimulated C-peptide concentration-time curve. Started Aug 2015; status: completed.
02
Drugs
NNC0114-0000-0005liraglutide
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2014-001215-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001215-39.